Press Releases InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
1.44 ^USD	-2.70%		-11.66%	-11.66%

May. 08	InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Transcript : InflaRx N.V. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators	May. 21	AQ
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update	May. 08	AQ
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	Apr. 30	AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed	Apr. 26	PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K	Apr. 25	PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	Apr. 24	AQ
InflaRx N : News Conference Call March 2024	Mar. 21	PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	Mar. 21	AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	Mar. 19	AQ
InflaRx Appoints Jan Medina as Head of Investor Relations	Feb. 22	AQ
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	Jan. 25	GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	Jan. 04	AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	Nov. 06	AQ
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 01	PU
INFLARX N : UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 - Form 6-K	Nov. 01	PU
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 01	AQ
InflaRx N : Desired blocking activity (>90%) of C5a-induced neutrophil activation at disease relevant C5a levels 24 hours post administration for doses of 30 mg to 240 mg - Form 6-K	23-09-11	PU
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904	23-09-11	AQ
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)	23-08-30	AQ
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update	23-08-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InflaRx N.V.

Equities

IFRX

NL0012661870

Press Releases

Filters